Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
By J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, Á. Lacave, U. Wagner, A. Stähle, G. Stuart, R. Kimmig and 10 more. Journal of Clinical Oncology, 2006
685 citations recorded by the source corpus.
Subfields: Oncology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/9ade3338ce76953adee5047963b70ac6bfd16a2f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
In Surgery
Citations in the corpus
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, methodology): “5, randomized platinum-sensitive patients to carboplatin (AUC of 4 on day 1) with gemcitabine (at a dose of 1000 mg/m(2) on days 1 and 8) or carboplatin alone (AUC of 5).(84) Compared with single-agent carboplatin, the combination arm had an improved response rate (31% vs 47%; P 1⁄4 .”
- OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. (2011, methodology): “0031).(5) Bevacizumab (BV), a monoclonal antibody targeting vascular endothelial growth factor (VEGF-A), has demonstrated activity in three phase II studies in ROC.”
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, background): “5 study protocol [286], most patients received 6 cycles of carboplatin in combination with PLD/paclitaxel/gemcitabine.”